Results 81 to 90 of about 83,135 (307)

Inter and intra-hemispheric structural imaging markers predict depression relapse after electroconvulsive therapy: a multisite study. [PDF]

open access: yes, 2017
Relapse of depression following treatment is high. Biomarkers predictive of an individual's relapse risk could provide earlier opportunities for prevention.
Abbott, Christopher C   +8 more
core   +3 more sources

Inert Catalytic Sites Unlocked by Micropollutants for Rapid Water Decontamination with Near‐Complete Chemical Utilization

open access: yesAdvanced Materials, EarlyView.
Micropollutants can act as molecular triggers that activate a newly designed and chemically inert Fenton‐like PKU‐24 catalyst for on‐demand singlet oxygen generation from peroxymonosulfate (PMS), enabling nearly complete peroxide utilization and selective micropollutant removal from complex real‐world wastewater.
Yu‐Hang Li   +7 more
wiley   +1 more source

Understanding vulnerability for depression from a cognitive neuroscience perspective: a reappraisal of attentional factors and a new conceptual framework [PDF]

open access: yes, 2010
We propose a framework to understand increases in vulnerability for depression after recurrent episodes that links attention processes and schema activation to negative mood states, by integrating cognitive and neurobiological findings.
De Raedt, Rudi, Koster, Ernst
core   +1 more source

Exploring Biological Risk Factors in Treatment-Resistant Depression

open access: yesPsychiatry International
Treatment-resistant depression (TRD) affects 20–30% of patients with major depressive disorder and presents a significant clinical challenge due to its biological diversity.
Francisco Javier Lievanos-Ruiz   +1 more
doaj   +1 more source

Brain SPECT perfusion and PET metabolism as discordant biomarkers in major depressive disorder

open access: yesEJNMMI Research, 2020
Background Brain SPECT perfusion and PET metabolism have been, most often interchangeably, proposed to study the underlying pathological process in major depressive disorder (MDD).
Maud Tastevin   +6 more
doaj   +1 more source

Engineered Heparinized GQDS/HPEI–Polyamide Membrane for Bilirubin Removal via One Step Anti Coagulation

open access: yesAdvanced Materials Interfaces, EarlyView.
A multifunctional heparinized polyamide membrane embedded with graphene quantum dots (GQDs) and hyperbranched polyethyleneimine (HPEI) is engineered for efficient bilirubin removal via a one‐step anticoagulation–adsorption process. The membrane demonstrates enhanced hemocompatibility, prolonged clotting times, and high bilirubin adsorption capacity ...
Abdur Rehman Mushtaq Ahmad   +6 more
wiley   +1 more source

Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. [PDF]

open access: yes, 2016
Adding supraphysiologic doses of levothyroxine (L-T4) to standard treatment for bipolar depression shows promise, but the mechanisms underlying clinical improvement are unknown.
Adli, M   +9 more
core  

Effect of neurostimulation on cognition and mood in refractory epilepsy. [PDF]

open access: yes, 2018
Epilepsy is a common, debilitating neurological disorder characterized by recurrent seizures. Mood disorders and cognitive deficits are common comorbidities in epilepsy that, like seizures, profoundly influence quality of life and can be difficult to ...
Chan, Alvin Y   +3 more
core   +1 more source

Case series: Clinical response of ketamine infusion in patients with treatment-resistant depression

open access: yesTelangana Journal of Psychiatry
Treatment-resistant depression (TRD) is one of the most debilitating conditions that does not respond to conventional pharmacotherapy. Ketamine is a recently used effective treatment option in depressive disorders with a novel mechanism of action. Still,
Pallavi Preetinanda   +6 more
doaj   +1 more source

Pharmacological Treatments for Patients with Treatment-Resistant Depression

open access: yesPharmaceuticals, 2020
Over a third of patients with major depressive disorder (MDD) do not have an adequate response to first-line antidepressant treatments, i.e., they have treatment-resistant depression (TRD).
Valerie L. Ruberto   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy